Kala Pharmaceuticals (KALA) Price & Analysis

Compare

1,467 Followers

KALA Stock Chart & Stats

Day’s Range― - ―

52-Week Range$2.92 - $20.60

Previous CloseN/A

Volume15.45K

Average Volume (3M)271.18K

Market Cap

$133.75M

Enterprise Value$28.99M

Total Cash (Recent Filing)$31.94M

Total Debt (Recent Filing)$11.14M

Price to Earnings (P/E)―

Beta1.22

Next Earnings

Nov 17, 2025

EPS Estimate

-1.27

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-1.71

Shares Outstanding7,021,040

10 Day Avg. Volume281,068

30 Day Avg. Volume271,177

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.22

Enterprise Value/Revenue114.14

Enterprise Value/Gross Profit-408.32

Enterprise Value/Ebitda-0.81

Forecast

1Y Price Target

$24.00

Price Target Upside25.98% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering5

Bulls Say, Bears Say

Bulls Say

Clinical Trial DesignThe unique 1-week run-in design of KALA's trial could lower the placebo effect, which is often a challenge in this space.

Market PotentialThere is no FDA-approved treatment for Persistent Corneal Epithelial Defect, highlighting a significant market opportunity for KPI-012.

Product EfficacyKPI-012 demonstrated rapid and significant pain relief, with all patients reporting zero pain score by Week 3 in the Phase 1b trial.

Bears Say

Capital RequirementsThe company may need to raise additional capital within the next 12 months to fund operations.

Financial PerformanceThe company had a net loss of $11.2M, slightly higher than the estimated loss.

Kala Pharmaceuticals News

Kala Pharmaceuticals price target raised to $35 from $12 at H.C. Wainwright

H.C. Wainwright raised the firm’s price target on Kala Pharmaceuticals (KALA) to $35 from $12 and keeps a...

11d ago

KALA

Kala Pharmaceuticals price target raised to $33 from $15 at Oppenheimer

Oppenheimer analyst Andreas Argyrides raised the firm’s price target on Kala Pharmaceuticals (KALA) to $33 from $15 and...

17d ago

KALA

Kala Pharmaceuticals initiated with an Outperform at Mizuho

Mizuho initiated coverage of Kala Pharmaceuticals (KALA) with an Outperform rating and $30 price target which provides over...

20d ago

KALA

Kala Pharmaceuticals management to meet with Piper Sandler

Meeting to be held in New York on September 9 hosted by Piper Sandler. Published first on TheFly...

23d ago

KALA

Kala Pharmaceuticals initiated with an Outperform at LifeSci Capital

LifeSci Capital initiated coverage of Kala Pharmaceuticals (KALA) with an Outperform rating and $23 price target Published first...

25d ago

KALA

Kala Bio appoints Bazemore as President, CEO, Director

KALA BIO announced that Todd Bazemore has been named President and Chief Executive Officer, CEO, of KALA BIO...

26d ago

KALA

Kala Pharmaceuticals Sets Date for Annual Meeting

Kala Pharmaceuticals ( ($KALA) ) has provided an update. On September 16, 2025, the Board of Directors of...

10d ago

KALA

Strategic Positioning and Trial Design Propel Kala Pharmaceuticals to ‘Buy’ Rating

LifeSci Capital analyst Francois Brisebois has maintained their bullish stance on KALA stock, giving a Buy rating yesterday....

10d ago

KALA

Kala Pharmaceuticals Appoints Todd Bazemore as CEO

An update from Kala Pharmaceuticals ( ($KALA) ) is now available. Kala Pharmaceuticals, a company in the biopharmaceutical...

26d ago

KALA

Optimistic Buy Rating for Kala Pharmaceuticals Driven by KPI-012 Trial Prospects and Financial Viability

Kala Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Yi Chen from...

2M ago

KALA

Kala Pharmaceuticals Reports Q2 2025 Financial Results

Kala Pharmaceuticals ( ($KALA) ) has released its Q2 earnings. Here is a breakdown of the information Kala...

2M ago

KALA

Kala Pharmaceuticals reports Q2 EPS ($1.71) vs ($3.16)

“The second quarter of 2025 was a pivotal period for KALA, marked by the completion of patient enrollment...

2M ago

KALA

Kala Pharmaceuticals initiated with a Buy at Ladenburg

Ladenburg initiated coverage of Kala Pharmaceuticals (KALA) with a Buy rating and $12 price target The company is...

3M ago

KALA

Promising Developments and Market Potential for Kala Pharmaceuticals’ KPI-012 Amidst Clinical and Regulatory Challenges

H.C. Wainwright analyst Yi Chen reiterated a Buy rating on Kala Pharmaceuticals today and set a price target...

3M ago

KALA

KALA FAQ

What was Kala Pharmaceuticals Inc’s price range in the past 12 months?

Kala Pharmaceuticals Inc lowest stock price was $2.92 and its highest was $20.60 in the past 12 months.

What is Kala Pharmaceuticals Inc’s market cap?

Kala Pharmaceuticals Inc’s market cap is $133.75M.

When is Kala Pharmaceuticals Inc’s upcoming earnings report date?

Kala Pharmaceuticals Inc’s upcoming earnings report date is Nov 17, 2025 which is in 50 days.

How were Kala Pharmaceuticals Inc’s earnings last quarter?

Kala Pharmaceuticals Inc released its earnings results on Aug 08, 2025. The company reported -$1.71 earnings per share for the quarter, missing the consensus estimate of -$1.703 by -$0.007.

Is Kala Pharmaceuticals Inc overvalued?

According to Wall Street analysts Kala Pharmaceuticals Inc’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Kala Pharmaceuticals Inc pay dividends?

Kala Pharmaceuticals Inc does not currently pay dividends.

What is Kala Pharmaceuticals Inc’s EPS estimate?

Kala Pharmaceuticals Inc’s EPS estimate is -1.27.

How many shares outstanding does Kala Pharmaceuticals Inc have?

Kala Pharmaceuticals Inc has 7,021,040 shares outstanding.

What happened to Kala Pharmaceuticals Inc’s price movement after its last earnings report?

Kala Pharmaceuticals Inc reported an EPS of -$1.71 in its last earnings report, missing expectations of -$1.703. Following the earnings report the stock price went up 3.073%.

Which hedge fund is a major shareholder of Kala Pharmaceuticals Inc?

Currently, no hedge funds are holding shares in KALA

Kala Pharmaceuticals Stock Smart Score

Outperform

Fundamentals

Return on Equity

-708.34%

Trailing 12-Months

Asset Growth

-41.48%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

Kala Pharmaceuticals Inc

Kala Pharmaceuticals, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for eye diseases. The company primarily operates within the healthcare sector, specializing in ophthalmology. Its core products are designed to address unmet needs in ocular health, including treatments for dry eye disease and inflammation following ocular surgery.

Kala Pharmaceuticals (KALA) Earnings & Revenues

Historic Earnings Reports

KALA Stock 12 Month Forecast

Average Price Target

$24.00

▲(25.98% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","19":"$19","36":"$36","10.5":"$10.5","27.5":"$27.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":24,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$24.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":12,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$12.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,10.5,19,27.5,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"Jun<br/>2025","12":"Sep<br/>2025","25":"Sep<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.19,13.944615384615384,15.69923076923077,17.453846153846154,19.20846153846154,20.963076923076922,22.71769230769231,24.472307692307695,26.22692307692308,27.981538461538463,29.736153846153847,31.49076923076923,33.245384615384616,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.19,13.098461538461539,14.006923076923076,14.915384615384616,15.823846153846153,16.732307692307693,17.64076923076923,18.549230769230768,19.45769230769231,20.366153846153846,21.274615384615387,22.183076923076925,23.091538461538462,{"y":24,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,12.19,12.175384615384615,12.16076923076923,12.146153846153846,12.131538461538462,12.116923076923076,12.102307692307692,12.087692307692308,12.073076923076924,12.058461538461538,12.043846153846154,12.02923076923077,12.014615384615384,{"y":12,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":7.99,"date":1711929600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.81,"date":1714521600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.28,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.99,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":6.72,"date":1733011200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":6.94,"date":1735689600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":9.2,"date":1738368000000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":5.73,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.72,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.52,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.84,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.5,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.19,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >